Myomatrix Stabilization Program
Duchenne Muscular Dystrophy (DMD)
Key Facts
About Strykagen
Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.
View full company profileAbout Strykagen
Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.
View full company profileAbout Strykagen
Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.
View full company profileAbout Strykagen
Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |
| EXONDYS 51 (eteplirsen) | Sarepta Therapeutics | Marketed |